Markets
Luke Kawa
3/27/25

US stocks retreat on tech- and tariff-fueled sell-off

Major indexes moved lower in a topsy-turvy session that saw the S&P 500 rebound from early losses only to stumble into the close. The benchmark US stock index fell 0.3%, the Russell 2000 gave back 0.5%, and the Nasdaq 100 slumped 0.6%.

Despite all the tariff headlines swirling, it was energy stocks and tech that performed the worst among S&P 500 sector ETFs.

Old-school US automakers tumbled on the imposition of tariffs, with those that sell a relatively elevated share of imported cars stateside (like General Motors) doing far worse than those with more final assembly completed domestically (like Ford). Some automakers with elevated domestic production and less exposure to imported parts, like Rivian and Tesla, even benefited from their rivals’ woes. And rental car companies Hertz and Avis boomed on the presumption that tariffs would hit auto production or raise prices (perhaps both!), lifting demand for rental cars that can be resold by these firms.

Airlines like American Airlines, Delta Air Lines, and United Airlines all hit the skids amid fresh data showing a precipitous drop-off in cross-border flight bookings between Canada and the US.

GameStop had its worst day since the June livestream hosted by Keith Gill (aka Roaring Kitty) after investors reacted poorly to its convertible note issuance, either facing massive dilution or a destruction in the option value that was assigned to its massive cash pile.

Meanwhile, Dollar Tree’s divestment of Family Dollar continues to be enthusiastically well received by traders, with the stock up double digits to be the S&P 500’s best performer on the day.

SoFi Technologies, a stock beloved by retail traders as of late, slumped.

AMD was a laggard in the semi space after Jefferies flagged a widening performance gap between it and Nvidia.

More Markets

See all Markets
markets

Tesla jumps after Elon Musk discloses buying 2.57 million shares, worth more than $1 billion

Tesla soared in early trading on Monday after CEO Elon Musk disclosed a purchase of 2.57 million shares in the company, according to a new SEC filing.

Per the filing, the "Elon Musk Revocable Trust,” for which the Tesla and SpaceX chief is the trustee, reported acquiring 2.57 million shares, taking its total ownership to 413.36 million shares as of September 12, 2025. The block of equity was bought at prices ranging from $371.38 to $396.54.

Earlier this month, the board of directors proposed an eye-watering pay package that could award the tech billionaire up to $1 trillion, assuming that very ambitious market cap and fundamental milestones are met.

markets

Hims & Hers falls after FDA commissioner says its Super Bowl ad breached regulations

Hims & Hers is falling in premarket trading after its Super Bowl ad from February was singled out as the “most overt” example of “brazen” marketing tactics among online pharmacies by FDA Commissioner Marty Makary.

The claim, made in an opinion piece written by Makary and published in the JAMA Network on Friday, highlighted the agency’s stricter enforcement policies on pharmaceutical advertisements.

“Equally brazen, online pharmacies are advertising drugs with only upsides mentioned, contributing to America’s culture of overreliance on pharmaceuticals for health,” wrote Makary. “This breach of FDA regulation was most overt earlier this year when Hims & Hers ran a Super Bowl ad highlighting the benefits of glucagon-like peptide-1 drugs without any mention of side effects or disclaimers.”

Hims’ Super Bowl ad touted its direct-to-consumer weight loss medications as “life-changing,” “affordable,” and “doctor-trusted,” billing its approach as “the future of healthcare.”

Google searches for the company spiked after the ad appeared during The Big Game.

Last week, President Donald Trump issued an executive order directing the Secretary of Health and Human Services to crack down on TV drug ads. It was initially unclear whether that order applied to telehealth companies.

Compounded drugs aren’t subject to the same regulatory burdens over their advertisements as branded, FDA-approved drugs made by pharmaceutical companies. For example, Hims can advertise generic Prozac for climax control (an off-label use) while the company that made the drug, Eli Lilly, cannot.

markets

Nvidia falls after Chinese regulator said it violated the country’s antitrust laws in 2020 deal

Nvidia dropped as much as 2.9% in early trading on Monday after China's State Administration for Market Regulation ruled that the chipmaker violated the country's antitrust laws after acquiring Mellanox Technologies, an Israeli-American network solutions supplier.

In 2020, Beijing approved Nvidia's ~$7 billion acquisition under the condition that the chipmaker would not discriminate against Chinese companies. Since then, Nvidia has had to redesign its chips to comply with the US government's regulations that temporarily banned the company from selling its advanced chips, including the H100.

Monday's preliminary finding from the SAMR comes amidst ongoing trade talks between US and Chinese officials in Madrid, with the tariff truce between the world's two largest economies set to expire in November.

As Sherwood’s Luke Kawa noted in August, China has appeared determined to “wean itself off of any dependence on Nvidia and US technology to develop its AI capabilities.”

According to Reuters, under Chinese antitrust law, companies can “face fines of between 1% and 10% of their annual sales from the previous year.” Nvidia’s sales in China generated $17.1 billion of revenue in its most recent fiscal year. Assuming the maximum penalty, the impact would be ~$1.7 billion, less than 1% of Wall Street’s forecast for Nvidia’s total revenue this fiscal year.

markets

Rocket lab soars to new record close amid rally for retail faves

Rocket Lab ripped by roughly 10% Friday to close at a new all-time high, riding an upturn of retail enthusiasm for a coterie of tech-themed favorites, even as the broader market was more or less flat on the day.

Goldman Sachs’ basket of “retail favorites” — its heaviest weights are Reddit, AppLovin, and Tempus AI — was the second-biggest gainer among the company’s flagship US equity baskets on Friday, rising about 1.6%. The S&P was almost dead flat.

It’s not Rocket Lab’s first retail rodeo, as the money-losing company has more than doubled this year and is up nearly 700% over the last 12 months.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.